Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1159/000513164 http://scihub22266oqcxt.onion/10.1159/000513164 33789273!8089443!33789273     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood+Purif 2022 ; 51 (1): 1-14 Nephropedia Template TP {{tp|p=33789273|t=2022. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment |pdf=|usr=}}{{33789273}} gab.com Text Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment JO: Blood Purif http://www.kidney.de/pget.php?&tw=1&pmid=33789273 #FOAvip Since early 2020, COVID-19 has wreaked havoc in many societies around the world. As of the present, the SARS-CoV-2-borne disease is propagating in almost all countries, affecting hundreds of thousands of people in an unprecedented way. As the name suggests, the novel coronavirus, widely known as SARS-CoV-2, is a new emerging human pathogen. A novel disease of relatively unknown origin, COVID-19 does not seem to be amenable to the currently available medicines since there is no specific cure for the disease. In the absence of any vaccine or effective antiviral medication, we have no tools at our disposal, but the method of quarantine, be it domestic or institutional, to hinder any further progression of this outbreak. However, there is a record of physicians in the past who practiced convalescent blood transfusion. To their awe, the method seemed to be useful. It is anticipated that these contemporary methods will outdo any other vaccination process in the time being, as blood transfusion is instead a cost-effective and time-friendly technique. Following a successful trial, this new approach of contemporary nature to a viral disease may serve as an emergency intervention to intercept infectious outbreaks and prevent an impending epidemic/pandemic. In this review, we document the most recent evidence regarding the efficiency of convalescent plasma and serum therapy on SARS, MERS, and particularly COVID-19, while discussing potential advantages and possible risks of such practice. Twit Text FOAVip Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment ????Blood Purif http://www.kidney.de/pget.php?&tw=1&pmid=33789273 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33789273 #FOAvip English Wikipedia <ref>{{Cite pmid|33789273}}</ref> Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment #MMPMID33789273 Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H Blood Purif 2022[]; 51 (1): 1-14 PMID33789273show ga Since early 2020, COVID-19 has wreaked havoc in many societies around the world. As of the present, the SARS-CoV-2-borne disease is propagating in almost all countries, affecting hundreds of thousands of people in an unprecedented way. As the name suggests, the novel coronavirus, widely known as SARS-CoV-2, is a new emerging human pathogen. A novel disease of relatively unknown origin, COVID-19 does not seem to be amenable to the currently available medicines since there is no specific cure for the disease. In the absence of any vaccine or effective antiviral medication, we have no tools at our disposal, but the method of quarantine, be it domestic or institutional, to hinder any further progression of this outbreak. However, there is a record of physicians in the past who practiced convalescent blood transfusion. To their awe, the method seemed to be useful. It is anticipated that these contemporary methods will outdo any other vaccination process in the time being, as blood transfusion is instead a cost-effective and time-friendly technique. Following a successful trial, this new approach of contemporary nature to a viral disease may serve as an emergency intervention to intercept infectious outbreaks and prevent an impending epidemic/pandemic. In this review, we document the most recent evidence regarding the efficiency of convalescent plasma and serum therapy on SARS, MERS, and particularly COVID-19, while discussing potential advantages and possible risks of such practice. |*Pandemics[MESH] |*SARS-CoV-2/immunology[MESH] |Antibodies, Viral/immunology/therapeutic use[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/epidemiology/history/prevention & control/*therapy[MESH] |Clinical Trials as Topic[MESH] |Convalescence[MESH] |Coronavirus Infections/therapy[MESH] |Forecasting[MESH] |History, 20th Century[MESH] |Humans[MESH] |Immunization, Passive/adverse effects/ethics/history/trends[MESH] |Influenza, Human/therapy[MESH] |Plasma[MESH] |Risk[MESH] |Serum[MESH]Convalescent Blood: Current Perspective on the Efficacy of a Legacy Ap(epmc).pdf DeepDyve Pubget Overpricing